Compounds > cyc 202
Page last updated: 2024-09-04

cyc 202 and 4,5,6,7-tetrabromobenzimidazole

cyc 202 has been researched along with 4,5,6,7-tetrabromobenzimidazole in 1 studies

Compound Research Comparison

Studies
(cyc 202)		Trials
(cyc 202)		Recent Studies (post-2010)
(cyc 202)		Studies
(4,5,6,7-tetrabromobenzimidazole)		Trials
(4,5,6,7-tetrabromobenzimidazole)		Recent Studies (post-2010) (4,5,6,7-tetrabromobenzimidazole)
979739344026

Protein Interaction Comparison

ProteinTaxonomycyc 202 (IC50)4,5,6,7-tetrabromobenzimidazole (IC50)
Ribosyldihydronicotinamide dehydrogenase [quinone]Homo sapiens (human)0.0794
Casein kinase II subunit alpha'Homo sapiens (human)0.81
Casein kinase II subunit betaHomo sapiens (human)0.81
Casein kinase II subunit alphaHomo sapiens (human)0.78
Dual specificity tyrosine-phosphorylation-regulated kinase 1AHomo sapiens (human)2.1
Casein kinase II subunit alpha 3Homo sapiens (human)0.93

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Jarhad, DB; Jeong, LS; Kim, HR; Mashelkar, KK; Noh, M1

Reviews

1 review(s) available for cyc 202 and 4,5,6,7-tetrabromobenzimidazole

ArticleYear
Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.
    Journal of medicinal chemistry, 2018, 11-21, Volume: 61, Issue:22

    Topics: Animals; Biological Products; Disease; Dyrk Kinases; Enzyme Activation; Humans; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases

2018